T he vial is familiar, the liquid inside could be water—but the price tag is a little more unusual. A shot of Zolgensma, a gene therapy for spinal-muscular atrophy, comes to $2.1m. It is one of a new generation of ultra-expensive medicines. Treatments for beta-thalassemia and haemophilia, two blood disorders, cost $2.8m and $3.5m, respectively. Their prices may be overtaken by gene therapies for sickle-cell disease expected to be approved this year, and one for Duchenne muscular dystrophy, which could be approved any day now.
小瓶很熟悉，内部的液体可能是水，但是价格标签有些不寻常。Zolgensma的镜头是一种用于脊柱肌肉萎缩的基因疗法，达到210万美元。它是新一代的超级廉价药物之一。β-地中海贫血和血友病的治疗方法，两种血液疾病，分别为280万美元和350万美元。预计今年将批准将批准镰状细胞疾病的基因疗法可能会超过他们的价格，而杜兴（Duchenne）肌肉营养不良症现在可以在任何一天都可以批准。
